Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.48 |
| ▸ | SIK2 | Q9H0K1 | 3/20 | 0.47 |
| ▸ | SIK3 | Q9Y2K2 | 3/20 | 0.47 |
| ▸ | SIK1 | P57059 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401377 | 0.89 | SRC (0.51) | FLT3SIK2SIK3SIK1SRC | |
| SCHEMBL5400820 | 0.88 | FLT3 (0.49) | FLT3SIK2SIK3SRCKDR | |
| SCHEMBL5394701 | 0.77 | SRC (0.53) | FLT3SRCKDR | |
| SCHEMBL5399308 | 0.75 | FLT3 (0.48) | FLT3TTK | |
| SCHEMBL5403454 | 0.75 | FLT3 (0.51) | FLT3TTK | |
| SCHEMBL5394394 | 0.74 | TTK (0.59) | FLT3TTK | |
| SCHEMBL5617945 | 0.74 | TTK (0.59) | FLT3TTK | |
| SCHEMBL5399718 | 0.73 | TTK (0.52) | FLT3TTK | |
| SCHEMBL5398230 | 0.72 | SMN1; SMN2 (0.51) | KDRTTK | |
| SCHEMBL5408035 | 0.72 | FLT3 (0.69) | FLT3TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | claimed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | FLT3 216/4885SIK2 325/4885SIK3 435/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | FLT3 215/4885SIK2 388/4885SIK3 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.